Evidence for altered neural activity patterns after MDMA-assisted therapy in adults with

chronic and severe post-traumatic stress disorder: a pilot study

S. Parker Singleton[1], Julie B. Wang, M.P.H, Ph.D.[2], Michael Mithoefer, M.D. [2,3], Colleen

Hanlon, Ph.D.[4], Mark S. George, M.D.[3,5], Annie Mithoefer[2], Oliver Mithoefer, M.D.[3], Allison R.

Coker, Ph.D. [2,6], Berra Yazar-Klosinski, Ph.D.[7], Amy Emerson [2], Rick Doblin, Ph.D.[7], Amy

Kuceyeski, Ph.D.[1,8]

[1] Department of Computational Biology, Cornell University, Ithaca, NY 14850, USA

[2] MAPS Public Benefit Corporations, San Jose, CA 95117, USA.

[3] Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina,

Charleston, SC 29425-0742, USA.

[4] Wake Forest School of Medicine, Winston-Salem, NC 27101 USA

[5] Ralph H. Johnson VA Medical Center, Charleston, SC 29425 USA

[6] Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

[7] Multidisciplinary Association for Psychedelic Studies, San Jose, CA 95117, USA.

[8] Department of Radiology, Weill Cornell Medicine, New York, New York 10021, USA

Corresponding Author: S. Parker Singleton; Email: sps253@cornell.edu

For submission as an Original Article to the *Frontiers in Psychiatry*

Total word count = <10,000 words

Role of Funding Sources: The clinical trial was sponsored by the Multidisciplinary Association

for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization. MAPS provided the

MDMA and fully funded this study from private and foundation donations. MAPS Public

Benefit Corporation (MAPS PBC), wholly owned by MAPS, was the trial organizer. SPS is

supported by the National Science Foundation Graduate Research Fellowship (Grant No. DGE-

1650441). AK is supported by the National Institutes of Health (RF1MH123232 and

R01NS102646).

Contributors: SPS and AK had full access to all the data in the study and take responsibility for

the integrity of the data and for the accuracy of the data analysis. BYK, AE, MM, RD conceived

and designed the clinical trial part of the study. MM & AM carried out experimental treatments

and recorded participant scripts. AE carried out sponsor oversight of data collection. CH and

MSG designed the imaging tasks and acquisition. CH, MSG, and OM oversaw the scanning and

data collection. SPS, AK, JW, AC drafted the paper. SPS carried out preprocessing, analysis, and

interpretation of data. RD obtained funding for the study. All authors contributed to the critical

review and final version of the manuscript.

Conflict of Interest: MM was paid as a contractor by MAPS PBC. AE, CP, AC, and JW

received salary support for full-time employment with MAPS PBC. BYK and RD received

salary support for full-time employment with MAPS. MM is on the Clinical Advisory Board of

Awakn Life Sciences.

Acknowledgements: The authors would like to thank the candidates who were willing to be

screened for eligibility; the participants in the trial who contributed their data; S. Sadler for her

dedication as the Study Coordinator; S. Braswell for serving as night attendant, M. Wagner and

J. Wymer for Independent Rater assessments. The authors would also like to thank: J. Holland

who supported this trial as a Medical Monitor; L. Jerome for her numerous and varied

contributions to this Clinical Development Program since prior to its inception with global

systematic literature reviews and medical coding; C. Hennigan for data management; R.

Matthews and B. Shechet for clinical operations and monitoring; J. Sonstroem and A. Seltzer for

randomization support and system programming; E. Sola, Y. Gelfand, and B. Cohen for

conducting adherence ratings to facilitate standardization of therapy; I. Gorman for development

of adherence ratings; A. Wilens for supporting video recording. The authors would like to thank

Dr. Edmund Higgins for catalyzing the first discussions about acquiring imaging data in the

MAPS trial.

ABSTRACT

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress

disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to

facilitate the therapeutic process, in part, by decreasing fear response during fear memory

processing while increasing extinction learning retention. The acute administration of MDMA in

healthy controls modifies recruitment of brain regions involved in the hyperactive fear response

in PTSD such as the amygdala and hippocampus. However, to date there have been no

neuroimaging studies aimed at directly elucidating the neural impact of MDMA-AT in PTSD

patients. We analyzed brain activity and connectivity via functional MRI during both rest and

autobiographical memory (trauma and neutral) response before and two-months after MDMA-

AT for PTSD in nine veterans and first-responders. We find that MDMA-AT (i) increases

amygdala-hippocampal resting-state functional connectivity, and (ii) reduces amygdala-

precuneus functional connectivity during neutral autobiographical memory recall in a manner

that co-varies with reduction of PTSD severity. These findings compliment previous research

indicating that amygdala-hippocampal functional connectivity is a potential target of MDMA-AT

and highlights other regions of interest related to memory processes. More research is necessary

to determine if these findings are specific to MDMA-AT compared to other types of treatment

for PTSD.

This study: NCT02102802   Parent-study: NCT01211405

Keywords: PTSD, MDMA, amygdala, hippocampus, precuneus, symptom provocation,

retrosplenial cortex, dissociation, insula, fMRI, functional connectivity, resting-state,

autobiographical memory.

1. INTRODUCTION

Post-traumatic stress disorder (PTSD), which can arise following exposure to a traumatic event

or repeated stressful events, impacts hundreds of millions of people, and is a debilitating social

and economic burden on individuals and their families. PTSD is associated with an increased

fear response (VanElzakker, Staples-Bradley, and Shin 2018) and distressing and intrusive re-

experiencing of traumatic memories (Ehlers 2010) that often serves as a barrier to the therapeutic

process. Current psychological therapies for PTSD have high dropout rates (Goetter et al. 2015),

especially trauma focused therapies (Lewis et al. 2020). When presented with trauma-related

stimuli, PTSD patients have shown increased activation in the precuneus, retrosplenial cortex,

anterior cingulate cortex (ACC), and amygdala compared to neutral stimuli (Sartory et al. 2013),

suggesting augmented recruitment of brain regions involved in self-referential processing

(Cavanna and Trimble 2006), salient autobiographical memory (Svoboda, McKinnon, and

Levine 2006; Spreng, Mar, and Kim 2009; Sestieri et al. 2011; Maddock 1999), and fear and

emotion (LeDoux 2003).

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is hypothesized to reduce

the fear response associated with re-experiencing traumatic memories, and therefore may

facilitate tolerable processing of traumatic content in patients with PTSD (Mithoefer et al. 2011).

Phase 2 and 3 trials have demonstrated promise for MDMA-AT as a viable treatment for PTSD

(Mitchell et al. 2021; Mithoefer et al. 2019; Wang et al. 2021; Jerome et al. 2020). In healthy

individuals, acute administration of MDMA has been shown to enhance positive and reduce

negative affect during the recollection of autobiographical memories, while preserving vividness

and emotional intensity (Carhart-Harris et al. 2014). In another study, MDMA was found to

preserve the memory accuracy when administered during both encoding and retrieval phases,

while attenuating the recollection of salient details for both positive and negative memories,

suggesting that MDMA alters emotional memory representations (Doss et al. 2018). Again in

healthy controls, MDMA was found to enhance fear extinction retention rates compared to

placebo when administered during extinction training phases (Maples-Keller et al. 2022). These

findings suggest that MDMA may aid the therapeutic process, in part, by enabling patient access

to emotionally challenging material and facilitating memory reconsolidation/fear extinction

processes (Feduccia and Mithoefer 2018).

The exact neurobiological underpinnings of PTSD and the specific effects of MDMA-AT in

individuals with PTSD have not been fully characterized, but several studies suggest the

amygdala and hippocampus play an important role. The amygdala is broadly associated with fear

response, and the hippocampus, associated with learning and memory, may provide contextual

information necessary for cognitive-affect during memory recall (LeDoux 2003; Harnett,

Goodman, and Knight 2020; Pitman et al. 2012). Sripada et al. (2012) found combat veterans

with PTSD have decreased amygdala-hippocampal resting-state functional connectivity (RSFC)

compared to combat veterans without PTSD, which the authors speculate may represent an

inability to contextualize affective information in PTSD. In healthy volunteers, the acute

administration of MDMA has the reverse effect, namely, increased amygdala-hippocampal

RSFC (Carhart-Harris, 2015). Despite evidence that RSFC between the amygdala and

hippocampus is implicated in PTSD and that this connection may be modulated by MDMA, no

study to date has shown relationships between changes in these regions' functional connectivity

and the therapeutic effects of MDMA-AT.

Herein, we describe results from a study of combat veterans and first-responders undergoing

MDMA-AT for PTSD in a randomized, double-blind, dose-response phase 2 clinical trial

(Mithoefer et al. 2018). Both resting-state and task-fMRI data, acquired while individuals

listened to a trauma-related or neutral script, were collected before and two months after

MDMA-AT (follow-up scans were collected after the blind was broken). Prior to analysis, we

hypothesized that MDMA-AT would increase RSFC between the amygdala and hippocampus

(Sripada et al. 2012; Carhart-Harris et al. 2015). We further hypothesized that, at baseline, brain

activity would be higher during the trauma-related listening task compared with the neutral

listening task in regions associated with autobiographical memory, fear, and emotion, such as the

precuneus, retrosplenial cortex, ACC, and amygdala, and that this effect would be reduced post-

treatment (Sartory et al. 2013). Finally, we hypothesized that the magnitude of the pre-to-post

treatment change in the functional connectivity of the amygdala and hippocampus would be

correlated with the magnitude of change in the pre-to-post treatment Clinician-Administered

PTSD Scale (CAPS-IV) total severity scores (Blake et al. 1990). Understanding the

neurobiological mechanisms of PTSD and how we may modulate these mechanisms is

imperative to developing effective, personalized treatments to reduce the burden of this disease.

2. METHODS

Figure 1: Study design. Subjects were assessed and imaged at the start of the study

(baseline). All subjects (low dose (LD), medium dose (MD), and high dose (HD)) underwent

three non-drug preparatory therapy sessions prior to their first MDMA dosing session. Each

MDMA session was followed by three non-drug integration therapy sessions. After MDMA

Session 2 and the subsequent integration sessions, subjects were assessed and the dosing

blind was broken. HD subjects completed their final set of drug and non-drug therapy

sessions unblinded, and LD/MD subjects crossed over into the HD arm where they

completed three sets of drug and non-drug sessions, now with the higher dose and unblinded.

All subjects were assessed and underwent MRI approximately two months following their

last HD MDMA session.

2.1 Trial design

The present study analyzed data from a sub-study (NCT02102802) of a Phase 2 randomized,

double-blind, dose-response trial of MDMA-AT in veterans and first responders with severe and

chronic PTSD (NCT01211405) (Mithoefer et al. 2018). A detailed study description of the

parent study can be found in (Mithoefer et al. 2018), here we summarize the study design.

Participants were recruited and screened between November 10, 2010 and January 29, 2015.

Veterans and first responders with severe PTSD as measured by a Clinician-Administered PTSD

Scale (CAPS-IV) (Blake et al. 1990) total severity score of 50 or more were enrolled in the study

and received three 90-minutes preparatory therapy sessions. In Stage 1, participants were

randomly assigned to three groups (1:1:2) that received blinded 30, 75 or 125 mg MDMA HCl

(followed by a supplemental half-dose unless withheld or declined) with therapy in two 8-hour

dosing sessions. Each of the dosing sessions was followed by three non-drug 90-minute follow-

up integration sessions that were one month apart. Psychological assessments were collected at

baseline and the primary endpoint which was one month after the second dosing session. In

Stage 2 of the study, the blind was broken and participants originally in the HD (125 mg) group

participated in a final open-label session at the same dose, while participants originally in the LD

(30 mg) or MD (75 mg) groups participated in three HD (100 – 125 mg) open-label sessions.

Each dosing session in Stage 2 was followed by three non-drug 90-minute integrative sessions.

Psychological assessments were collected approximately 2 months and 12 months after the final

dosing session in Stage 2. Psychological assessment included the clinician-administered

measures CAPS-IV and Global Assessment of Functioning (GAF; general psychological

function; Guze 1995), and self-reported measures including Beck Depression Inventory-II (BDI-

II; depression symptoms; Beck et al. 1996), Pittsburgh Sleep Quality Index (PSQI; sleep quality;

Buysse et al. 1989), Post-Traumatic Growth Inventory (PTGI; perceived growth following

trauma; Tedeschi and Calhoun 1996), and the Dissociative Experiences Scale II (DES-II;

symptoms of dissociation; Carlson and Putnam 1993).

Participants in the parent study were able to opt into the MRI-based sub-study after which they

provided written informed consent approved by the Medical University of South Carolina

Institutional Review Board. They were screened for additional neuroimaging related eligibility

criteria and were excluded for any conditions that could render MRI unsafe. Following baseline

CAPS-IV assessment in the parent study, sub-study participants worked with investigators to

create two scripts: one describing a personally traumatic event and one reflecting their typical

morning routine at home. Two audio recordings, each six minutes in length, were created from

the participant's reading of each script. Each audio recording was divided into two 3-minute

blocks for the task-fMRI. All participants were imaged at baseline, prior to therapy, and again at

the follow-up visit two months after their final dosing session. LD (N = 2) and MD (N = 2)

participants were additionally imaged after the primary endpoint visit in Stage 1 (one month

following their second dosing session), however the small sample sizes prevented any

meaningful analysis with these scans. The present analysis focuses on the pre- and post-therapy

effects of MDMA-AT on fMRI biomarkers, and thus uses the scans collected at pre-treatment

(baseline) and at least 2 months after the largest dose of MDMA (follow-up).

2.2 MRI acquisition

At each scanning session, participants underwent MRI on a 32 channel 3T Siemens system. T1

anatomical scans with TR/TE=1900/2.34 ms and 0.9x0.9x1.0 mm voxel size were collected,

followed by two identical task fMRI (design described below) (TR/TE = 2200/35ms, 3.0 mm

isotropic voxel size, length of each scan = 14:25 min) and one resting state fMRI (TR/TE =

2000/30ms, 3.3x3.3x3.0 mm voxel size, length = 5:00 min).

Participants' 6-minute trauma and neutral audio scripts were divided into two three-minute

trauma and neutral blocks each (See 2.1 Trial design for description of audio recordings). During

fMRI, participants were presented with the visual cue "allow" and instructed to allow themselves

to experience the scripts as their audio recordings were played for both neutral and trauma

blocks. Each task scan had an alternating block design (neutral 1, trauma 1, neutral 2, trauma 2)

with an 18 second 'rest' period at the start of the scan and between each block, and about a

minute of rest at the end of the scan. The precise length of each audio block was 2.95 min.

2.3 Image preprocessing

FreeSurfer (Dale, Fischl, and Sereno 1999) was applied to the T1s to create white matter (WM),

gray matter (GM) and cerebrospinal fluid (CSF) segmentations. FMRIB Software Library (FSL)

(Smith et al. 2004) was used for 1) brain extraction, 2) registration between T1s and fMRI's

(brain-boundary registration, non-linear, full-search), 3) high-pass filtering 4) slice-time and 5)

motion correction.

2.4 Activation analysis: brain response to trauma versus neutral audio listening

FSL's FEAT tool (Woolrich et al. 2004) was used for fitting a general linear model (GLM) to the

voxelwise timeseries for each task scan after spatial smoothing using a Gaussian kernel function

(6 mm full width at half maximum (FWHM)). We constrained our search to four bilateral

regions of interest (ROIs) in PTSD symptom provocation (Sartory et al. 2013) using the

Desikan-Killiany atlas (Desikan et al. 2006): the precuneus, isthmus cingulate (containing the

retrosplenial cortex), rostral anterior cingulate, and amygdala. For 1st- level analysis, models

were generated for the neutral block, the trauma block, and a contrast of the two (trauma >

neutral). Confound explanatory variables (EVs) included the temporal derivative of each block, 5

nuisance regressors each for WM and CSF signal, and 6 directions of motion (x/y/z mm/rad).

Second-level analysis averaged the models from each of the two task scans performed at each

time point. Third-level analyses, using a two-sided, one-sample t-test (FSL randomize; Winkler

et al. 2014) identified group-level response for the contrast model (i) at baseline, and (ii) at the

two-month follow-up. A final third-level analysis (iii) compared the group-level responses to the

contrast model at baseline and follow-up using a two-sample, two-sided, paired t-test (FSL

randomize; Winkler et al. 2014). Third-level results were corrected for multiple comparisons

using threshold-free cluster enhancement (TFCE; $p < 0.05$) (Smith and Nichols 2009).

2.5 Functional connectivity

Functional connectivity here is defined as the statistical relationship (in this case Pearson

correlation) between two brain regions' blood-oxygen level dependent (BOLD) time series

extracted from fMRI scans.

Prior to extraction of functional connectivity, in addition to the preprocessing steps taken in 2.3,

fMRI data were further denoised using an in-house pipeline

(https://github.com/kjamison/fmriclean). FMRIs were bandpass filtered and regressed for 24

motion confounds (Friston et al. 1996), 5 nuisance regressors each for WM and CSF, and one for

global GM signal. The first five frames (scanner start-up noise) and confound frames were

discarded. Gray matter was further parcellated into 68 cortical and 16 subcortical regions of

interest (ROIs) (Desikan et al. 2006). The cerebellum was excluded due to incomplete scan

coverage of this structure.

In the pre-hoc analysis of the resting-state fMRI data, resting-state functional connectivity

(RSFC) between the right and left amygdala and right or left hippocampus was evaluated. One-

tailed, paired *t*-tests were used to compare the 4 RSFC measures before and after MDMA-AT.

Functional connectivity during task fMRI between the four regions of interest (bilateral

amygdala and hippocampus) and the rest of the brain was assessed. This was done with the time-

series extracted from the (a) neutral block and (b) trauma block, separately. See the

Supplemental Information for functional connectivity analysis using the entire scan. Group-level

changes from pre- to post-therapy in the strength of functional connections were assessed using

two-tailed, paired *t*-tests.

After obtaining whole-brain activation and functional connectivity results from the task data,

which highlighted the precuneus as a region of interest, we performed a post-hoc analysis of the

RSFC between both amygdalae and hippocampi with the right and left precuneus. We used two-

tailed, paired *t*-tests to compare the 8 RSFC measures before and after MDMA-AT.

Pearson correlations were calculated between individuals' changes in functional connection

strength and change in CAPS-IV total severity scores (follow-up – baseline). All *p*-values were

corrected for multiple comparisons using the Benjamini-Hochberg algorithm (Benjamini and

Hochberg 1995) where indicated.

3. RESULTS

3.1 CAPS significantly decreases after HD MDMA-AT

Ten participants enrolled in the sub-study, and one withdrew consent after baseline due to

anxiety in the MRI scanner, leaving nine participants with MRI data at both time points (6 male,

aged 41.3; standard deviation (SD) = ± 10.9 years; 8 veterans and 1 first responder). All

participants self-reported moderate depression as indexed by BDI-II (Beck et al. 1996). One

subject's baseline resting-state fMRI was truncated due to technical issues, leaving eight subjects

for resting-state analysis and nine for the task fMRI analysis. Mean (SD) CAPS-IV total severity

scores of the nine individuals pre- and post-MDMA-AT were 86 (± 16) and 39 (± 25),

respectively, representing a significant decrease in PTSD symptom severity between the two

time points (Figure 2; N=9, t = 6.36, p = 0.00022). The average percent decrease in CAPS was

57 (± 26)%. Results on all participants enrolled in the Phase 2 parent trial have been previously

reported (Mithoefer et al. 2018).

Figure 2: Patient CAPS-IV total severity scores at the baseline (pre-therapy) and two-month

follow-up (post-therapy) scanning sessions. Black and red lines indicate group means and

medians, respectively. A significant reduction is PTSD severity was observed after MDMA-AT

(baseline > follow-up; N=9, $t = 6.36$, p = 0.00022).

3.2 Amygdala-hippocampal RSFC increases after HD MDMA-AT

The RSFC was assessed between the amygdala and hippocampus before and after MDMA-AT

and the strengths of these connections are illustrated in Figure 3. All connections trended

towards increased functional connectivity after therapy compared to before therapy (using a one-

sided paired t-test), with left amygdala to both hippocampi having significant increases ($t = $-

2.97, uncorrected p = 0.0104, pFDR = 0.0416 and $t = $-2.11, uncorrected p = 0.0361, pFDR =

0.0722 for left and right hippocampus, respectively. N=8).

Figure 3: RSFC between the amygdala and hippocampus before and after MDMA-AT. P-values from a one-sided, paired t-test have been corrected for multiple comparisons. Black and red lines indicate group means and medians, respectively. (N = 8; t-statistics indicate baseline > follow-up; * uncorrected p < 0.05, ** pFDR < 0.05).

Individual-level pre-to-post-therapy changes between the strength of these functional connections were then correlated with changes in CAPS scores. All four correlations showed that

larger increases in connectivity strength after therapy were associated with larger reductions in

symptom severity (improvement in PTSD). Only one of these (right amygdala to left

hippocampus) was significant before correction (N = 8; R = -0.773, uncorrected p = 0.0244,

pFDR = 0.0976).

3.3 Increased precuneus and retrosplenial cortex activation during symptom provocation

We compared script-driven activations (trauma > neutral) in four pre-determined ROIs: the

bilateral precuneus, isthmus cingulate (anatomical gyrus containing the retrosplenial cortex),

rostral anterior cingulate cortex (ACC), and amygdala (Figure 4A). These regions have

previously been shown to activate more during trauma-related stimuli than neutral stimuli in

PTSD patients (Sartory et al. 2013). Before therapy, there tended to be stronger responses to the

trauma script versus the neutral script in our ROIs, as evidenced by the generally positive t-

statistics (Figure 4B). After correction using threshold free cluster enhancement (TFCE), there

was significantly greater activation during the trauma scripts compared to the neutral scripts in a

cluster on the border of the bilateral precuneus and bilateral isthmus cingulate/retrosplenial

cortex (Figure 4B, black outline; N=9, cluster corrected, p<0.05). After therapy, there was less

contrast between the two scripts, and no significant clusters (Figure 4C). Finally, we assessed the

differences in the contrast model before and after therapy (baseline > follow-up). There was

generally greater (positive) contrast between the trauma and neutral scripts at baseline than at

follow-up, however no clusters survived correction for multiple comparisons (Figure 4D).

Figure 4: Group-level activation contrasts for trauma versus neutral script listening tasks. (A) Results were constrained to four bilateral anatomical ROIs from PTSD symptom provocation literature (Sartory et al. 2013): the precuneus, isthmus cingulate (retrosplenial cortex), rostral anterior cingulate cortex (ACC), and the amygdala (Desikan et al. 2006). Panels B, C, & D show the t-statistic from the corresponding comparison. (B) Pre-therapy there is a significant cluster within the bilateral precuneus/isthmus cingulate (outlined in black; center of gravity: MNI -1, -51, 28, 60 voxels (1620 mm^3), peak z-value = 2.89; $p < 0.05$, cluster corrected; N = 9). (C) There were no significant activation contrast clusters after therapy. (D) Comparing the group-level contrasts between time points (baseline > follow-up), there were no clusters that met significance thresholds after correction.

3.4 MDMA-AT associated changes in task functional connectivity

We compared the pre- and post-therapy strength of amygdalae and hippocampal functional connections with the rest of the brain during the neutral and trauma blocks separately (Figure 5A/B). There were several connections with a trend for change from pre- to post-therapy (SI

Tables 1 and 2). After correction for multiple comparisons, the left hippocampus and left caudal

middle frontal gyrus functional connectivity during trauma recall was significantly reduced at the

two-month follow-up post-therapy (N = 9, t = 7.13, pFDR = 0.0082).

Figure 5: Paired t-statistics shown for differences in functional connectivity between all brain

regions and the amygdalae and hippocampi during (A) neutral memory audio listening and (B)

trauma memory audio listening (N = 9; baseline > follow-up; * two-tailed p < 0.05, uncorrected;

** pFDR < 0.05, corrected).

Individual-level pre-to-post therapy changes in the functional connections calculated in the

previous section were then correlated with the individual-level reductions in CAPS scores

(Figure 6). Many significant correlations (corrected and uncorrected) were positive, meaning that

larger reductions in connectivity from pre- to post-therapy corresponded to larger improvements

in PTSD symptomology (SI Tables 3 and 4). Following correction for multiple comparisons, the

two positive correlations between changes in right amygdala and bilateral precuneus connectivity

during neutral memory recall and CAPS scores remained significant (Figure 6C).

Figure 6: Pearson correlation values between changes in each functional connection during (A)

neutral memory audio listening and (B) trauma memory audio listening and changes in CAPS

scores. (C) Scatter plots of the significant correlations from the neutral condition (N = 9; follow-

up – baseline; * p-value < 0.05, uncorrected; ** pFDR < 0.05, corrected).

3.4 Post-hoc analysis of amygdala and hippocampus RSFC with the precuneus

As change in the task-based functional connectivity between the amygdala and precuneus was found to be related to improvement of PTSD severity scores, we performed post-hoc analyses of RSFC between the precuneus and amygdalae and hippocampi to identify 1) any changes before and after therapy and 2) any correlations between change in functional connectivity and change in CAPS. We did not find any pre- and post-therapy changes in functional connection strength of amygdalae or hippocampi with the precuneus. Pre-to-post therapy changes in the RSFC between the right amygdala and both the right and left precuneus correlated with the reductions in CAPS scores, albeit at a trend level (N = 9; R = 0.687, uncorrected p = 0.0599; R = 0.667, uncorrected p = 0.0709 for the right and left precuneus, respectively), reflecting the task-based functional connectivity finding during the neutral block.

3.5 Correlations with other outcome measures

Although not the primary focus of our analysis, we also repeated the previous correlations using other secondary outcome measures in place of CAPS-IV total severity scores. Namely, changes between baseline and follow-up in the BDI-II (depression symptoms), the PSQI (sleep quality), the PTGI (perceived growth following trauma), the DES-II (symptoms of dissociation), and the GAF (general psychological function) were used. Following correction for multiple comparisons, only three correlations remained significant and, notably, all three were between changes in task functional connectivity and symptoms of dissociation. During the neutral task, reduction in functional connectivity between the left hippocampus and the left pre- and post-central gyrus (motor) at follow-up compared to baseline correlated with reductions in

dissociative symptoms (lower DES-II scores; pre-central: R = 0.930, pFDR = 0.0226; post-

central: R = 0.904, pFDR = 0.0346). During the trauma task, reduction in functional connectivity

between the right amygdala and right insula at follow-up compared to baseline correlated with

reduction in dissociative symptoms (R = 0.925, pFDR = 0.029).

DISCUSSION

We report signatures of brain response during rest and audio listening task in eight veterans and

one first-responder with clinically diagnosed chronic and severe PTSD before and two-months

after MDMA-assisted therapy. We found a significant reduction in CAPS-IV total severity

scores after therapy, indicating our sub-study participants mirrored the results from the parent

study (Mithoefer et al. 2018). RSFC between the amygdala and hippocampus was significantly

strengthened post-therapy, providing more evidence that modulation of amygdalae-hippocampal

RSFC may be an important component of MDMA-AT for PTSD (Sripada et al. 2012; Carhart-

Harris et al. 2015). We also found participants had increased activation in the

precuneus/retrosplenial cortex while listening to traumatic versus neutral memory narrations pre-

therapy, and that no significant contrast existed after MDMA-AT (the comparison between the

two time points was also not significant). Finally, the pre- to post-therapy reduction in functional

connectivity between the right amygdala and right precuneus during neutral memory audio

strongly and significantly correlated with PTSD symptom improvement.

Previous work quantifying functional connectivity in PTSD (Sripada et al. 2012) and acute

MDMA administration in controls (Carhart-Harris et al. 2015) suggests one mechanism of

MDMA-AT may be to increase pathologically lowered amygdala-hippocampal RSFC (Feduccia

and Mithoefer 2018). The amygdala is associated with fear expression, threat recognition, and

heightened response to emotional memories and is often dysregulated in patients with PTSD

(LeDoux 2003; Pitman et al. 2012; Liberzon et al. 1999; Etkin and Wager 2007; Bremner et al.

2005; Harnett, Goodman, and Knight 2020). The hippocampus also plays a central role in PTSD

as it is thought to provide contextual information important for cognitive-affect during memory

recollection (Harnett, Goodman, and Knight 2020; Pitman et al. 2012). Sripada et al (2012)

found combat veterans with PTSD had reduced amygdala-hippocampal RSFC compared to

combat-exposed controls, leading them to speculate that this may relate to an inability to

contextualize affective information in PTSD. Carhart-Harris et al (2015) demonstrated that

amygdala-hippocampal RSFC is increased acutely in MDMA administration compared to

placebo and this increase occurred in a manner that correlated with the drug's subjective effects

at a near-significant level, leading these researchers to propose that this functional connection

was a primary target of MDMA-AT. Prior to our analysis (although after the study was designed

and the data collected), we hypothesized that the RSFC between the amygdala and hippocampus

would be higher after MDMA-AT compared to pre-therapy levels, which we confirmed. We also

found that the amount of increased amygdala-hippocampal RSFC after MDMA-AT positively

correlated with PTSD symptom improvement at a near-significant level. Our current findings

provide further evidence that one mechanism driving MDMA-AT's treatment of PTSD could be

an increase in amygdala-hippocampus RSFC.

We next sought to study brain-response during autobiographical memory listening to draw

additional conclusions about MDMA-AT's effects in individuals with PTSD. Before therapy,

participants had larger activation in a cluster of voxels located in the bilateral precuneus and

retrosplenial cortex during an individualized trauma script listening task compared to neutral

audio script listening. The precuneus is involved in self-processing operations (e.g. first-person

perspective taking), episodic memory retrieval, and visual-spatial imagery (Cavanna and Trimble

2006). Its activation is often correlated with activation of the retrosplenial cortex (Cauda et al.

2010), which is implicated in autobiographical memory recollection (Svoboda, McKinnon, and

Levine 2006; Spreng, Mar, and Kim 2009). The retrosplenial cortex is also found to be

consistently activated by emotionally salient stimuli, and has been proposed to play a role in the

interaction between emotion and memory (Maddock 1999). We conjecture that increased

activation in these regions during traumatic compared to neutral audio listening (Figure 4B)

could be related to an increased intensity of the recollection or re-experiencing of traumatic

memories compared to neutral ones for patients before therapy. At 2-month follow-up to

MDMA-AT, there was no significant difference in the trauma vs neutral script activation of this

area (Figure 4C). Although the longitudinal comparison of these two time points also showed no

significant difference after correction for multiple comparisons, the positive t-statistics indicate

that the contrast between trauma and neutral was generally larger at baseline, particularly in the

precuneus/retrosplenial cortex and the anterior cingulate cortex (ACC) (Figure 4D). Larger

studies may allow more statistical power to identify longitudinal differences if they do indeed

exist. These findings are consistent with previous studies — a meta-analysis by Sartory et al

(2013) (the source of our ROIs) found that PTSD patients had greater activations in the

precuneus and retrosplenial cortex, as well as the bi-lateral amygdala and anterior cingulate

cortex during trauma-related stimuli compared to neutral stimuli. In addition, other longitudinal

studies of individuals with PTSD have found the amount of decrease in precuneus/posterior

cingulate cortex (PCC; of which the isthmus cingulate/retrosplenial cortex is a part) activation

during symptom provocation at the end of study to be correlated with amount of reduction in

symptom severity (Garrett et al. 2019; Ke et al. 2016).

PTSD is often associated with hyperactivity in the amygdala (Pitman et al. 2012); the acute

administration of MDMA in healthy volunteers decreases blood flow to the amygdala during rest

(Carhart-Harris et al. 2015) and attenuates its response to angry faces (Bedi et al. 2009). We had

hypothesized that we would observe hyperactivity of the amygdala to trauma versus neutral

scripts at baseline and that MDMA-AT would attenuate this response, however we observed

neither. It is important to note inconsistencies in the literature here. Amygdala hyperactivity in

PTSD is not always observed, possibly due to differences in subtypes, sex, cultural

representations, or choice of paradigm (van Huijstee and Vermetten 2018; Lanius et al. 2001;

Lanius et al. 2002; Helpman et al. 2021; Chiao et al. 2008; Liddell and Jobson 2016).

Additionally, while MDMA did suppress amygdala activity during rest and in response to angry

faces as previously mentioned, there was no observed impact on its response to autobiographical

memories (Carhart-Harris et al. 2014). While activation-based analyses deserve continued

attention in future studies to rectify these inconsistencies, functional connectivity is a

complimentary approach we can use to extract additional information from fMRI.

In a task-free setting, amygdala activity has been found to be anti-correlated with activity in

areas involved in effortful regulation of affect, including the precuneus (Roy et al. 2009; Zhang

and Li 2012). In healthy adults, amygdala-precuneus functional connectivity increases following

the acute exposure to social stress (Veer et al. 2011, 2). This functional connection has been

implicated in mood disorders including depression (Cullen et al. 2014; K. D. Young et al. 2018;

Wei et al. 2018; Feurer et al. 2021; Peng et al. 2020), bipolar disorder (Stoddard et al. 2015;

Singh et al. 2015) and anxiety (Strawn et al. 2012; Toazza et al. 2016), childhood emotional

maltreatment (Werff et al. 2013), and PTSD (Nicholson et al. 2015; Bluhm et al. 2009; R. A.

Lanius et al. 2010). One study found adults who experienced childhood emotional maltreatment

show increased (decreased magnitude negative) connectivity between the amygdala and

precuneus compared to controls (Werff et al. 2013), and another found PTSD patients with

dissociative sub-type had increased connectivity compared to PTSD patients without dissociative

sub-type (Nicholson et al. 2015). Here, we find a strong, significant correlation between pre- to

post-therapy decreases in right amygdala-precuneus functional connectivity during neutral

scripts and pre- to post-therapy decreases in CAPS-IV. Attenuated correlation between the

activity patterns of these two regions at follow-up possibly suggests a decreased intensity of

recalled events, less 're-experiencing', or reduced negative affect.

It is worth noting here that *increased* amygdala-precuneus functional connectivity during both

rest and positive autobiographical memory recall was found to correlate with improved

depressive symptoms in adults using real-time fMRI neurofeedback targeting amygdala

activation (K. D. Young et al. 2018). Depression is characterized by decreased arousal

(depressed mood) and diminished positive affect, therefore these findings may be reflective of an

increased emotional response to positive memories that is associated with symptom

improvement (Dunn et al. 2020). However, another study in adolescents found that those with

depression had greater amygdala-precuneus RSFC compared to healthy controls (Cullen et al.

2014), so replication is necessary. It seems likely that this functional connection is relevant to

cognitive affect in mood disorders, however more research is needed to determine if these

findings are reflective of differences in depression and PTSD, or the context in which the study

populations were being imaged (i.e. studying processes and tasks related positive affect in the

case of depression and negative affect in the case of PTSD). Considering the co-morbidity of

depression and PTSD (Brady et al. 2000), amygdala-precuneus functional connectivity may

deserve increased attention in future studies.

Also of interest were the significant correlations found between reduction in symptoms of

dissociation and changes in task functional connectivity. During neutral memory audio listening,

the reduction of left hippocampus to both left motor (pre- and post-central) gyri functional

connectivity correlated with reduction in dissociative symptoms. These two functional

connections appear to be higher in cases of trait anxiety (Yang et al. 2017). Lastly, MDMA

acutely alters insula functional connectivity (Walpola et al. 2017), a region implicated in anxiety

(Etkin and Wager 2007). Baur et al. (2013) provided evidence that amygdala-insula functional

connectivity indexes individual differences in state anxiety. Here, we find that reductions in right

amygdala-insula functional connectivity during trauma audio listening after MDMA-AT

correlates with reductions in dissociative symptoms, possibly relating to reduced anxiety or

dissociation during traumatic memory recall after treatment.

PTSD is characterized by decreased fear extinction in response to trauma-related stimuli. One

possible mechanism through which MDMA-AT operates is enhanced reconsolidation and/or fear

extinction processes (Feduccia and Mithoefer 2018). Several studies with MDMA implicate

reconsolidation or fear extinction processes, and while it is currently unclear whether MDMA

acts on only one or both, it is important to note that the two interact (Suzuki et al. 2004). Rodent

models have demonstrated that the administration of MDMA prior to extinction learning

enhances post-acute extinction retention and this effect is blocked by acute and chronic treatment

with a serotonin transporter inhibitor (M. B. Young et al. 2015; B. Young et al. 2017). Hake et

al. (2019) found that MDMA administered during extinction learning phases did not enhance

fear extinction memory, while MDMA administration during reconsolidation phases resulted in

prolonged reductions in conditioned fear. In addition, MDMA administered prior to trauma-cue

exposure (reconsolidation phase) in rodents resulted in reduced stress-related behavioral

responses 7 days later (Arluk et al. 2022). A randomized, controlled clinical trial in healthy

humans found that those who were administered MDMA (100 mg) prior to extinction learning

showed a higher rate of total extinction retention 48 hours later compared to the placebo group

(Maples-Keller et al. 2022). Doss et al. (2018) found that 1 mg/kg of MDMA in healthy humans

attenuated the encoding and retrieval of salient details from positive and negative stimuli (but not

neutral stimuli), suggesting an ability for MDMA to alter emotional memory representation.

Interestingly, a fMRI study in healthy humans found decreased activation in the precuneus/PCC

during fear extinction learning (Ridderbusch et al. 2021), regions highlighted by our present

study and others in PTSD (Garrett et al. 2019; Ke et al. 2016) .

LIMITATIONS

The small sample size of the present study and the lack of a control population (e.g. trauma-

exposed controls) may decrease the generalizability of these findings. The trial design was

placebo-controlled for dose-response (low, medium, and high), however, the follow-up scans

used in this study were after the breaking of the blind and dose cross-over (low/medium to high)

had occurred. For neuroimaging studies, comparisons with control populations are helpful for

contextualizing longitudinal changes in brain response and provide information about whether

changes in patient populations represent an abnormal response being restored to normality or a

compensatory mechanism. In addition, multi-point imaging of healthy control or non-treatment

(placebo) groups allow for the quantification of test-retest variability.

Here it must be discussed that PTSD is a disorder exhibiting at least two major sub-types with

characteristically opposing phenomenological and physiological responses to symptom

provocation, which may explain inconsistencies in the PTSD neurobiology literature (van

Huijstee and Vermetten 2018). In addition to sub-type heterogeneity, males and females with

PTSD may also differ in their neural responses (Helpman et al. 2021). Limited by our sample

size, we did not investigate these sub-groups in this study.

The accepted standard for assessing PTSD severity is the Clinician-Administered PTSD Scale

(Blake et al. 1990). Specifically, CAPS-IV was used in this study. CAPS-IV involves an hour-

long semi-structured interview with a clinician and, though comprehensive, faces limitations. In

their baseline CAPS-IV assessment, and subsequently thereafter, patients were asked to refer to

an index trauma that was measured throughout the study. This may present an issue in accurately

assessing global PTSD severity if an adjacent or un-related trauma surfaces during therapy and

becomes the prominent driver of their symptoms. These issues, combined with difficulty in

blinding and expectancy effects, present additional challenges in accurately mapping fMRI

metrics to clinical outcomes. At the same time, these challenges motivate the need to improve

our ability to detect biomarkers of PTSD to accompany psychological indexes.

The task design used in this study examined differences in brain response to personalized audio

scripts generated from narrations of traumatic and mundane (neutral) memories. Many different

stimuli have been used in fMRI studies of PTSD (R. A. Lanius et al. 2006; Sartory et al. 2013;

Patel et al. 2012), each providing its own unique advantages and disadvantages. Our present

design optimizes personal relevance of the stimuli; however, this has the consequence of

presenting each subject with a different set of stimuli, whereby brain responses within each block

are not time-locked across participants. Also, it has previously been shown that PTSD survivors

take longer to retrieve unrelated autobiographical information when listening to taped imagery

scripts of their traumatic memories (Kleim, Wallott, and Ehlers 2008). This suggests the

possibility that those with the most severe PTSD will take the longest to cognitively transition to

the neutral block from the trauma block. If this is true, then there would perhaps be an inverse-

"U" relationship between PTSD severity and contrast between the trauma and neutral conditions,

if the blocks are not spaced far enough apart to allow adequate time for patients to return to a

baseline level of cognitive functioning.

Finally, the pre-specified aim of this study was to estimate longitudinal (baseline to 2-months

after final MDMA session) changes in ROI response to traumatic audio scripts. Between the start

of data collection and analysis, new literature emerged (Carhart-Harris et al. 2015) implicating

amygdala-hippocampus RSFC as a potential target of MDMA-AT, compelling us to expand our

analysis beyond the pre-specified aims.

CONCLUSION

We report functional brain changes associated with MDMA-AT in participants with PTSD. We

provide further evidence that MDMA-AT may act through strengthening the RSFC between the

amygdala and hippocampus, a connection which is weaker in PTSD populations (Sripada et al.

2012) and increased acutely by MDMA in healthy volunteers (Carhart-Harris et al. 2015). We

also provide preliminary evidence that MDMA-AT alters amygdala and precuneus response

during symptom provocation. These regions, associated with fear response and self-referential

processing, respectively, are commonly found to be hyperactive in PTSD patients (Sartory et al.

2013; Patel et al. 2012). However, the reduction of right amygdala-precuneus functional

connectivity co-varying with symptom reduction in PTSD is a novel finding. More research is

necessary to confirm this result and determine if this is an effect specific to MDMA-AT, or if it

would be found in other longitudinal treatment cohorts as well.

----------------------- *END OF MANUSCRIPT* ------------------------

REFERENCES

Arluk, Shira, Michael A. Matar, Lior Carmi, Oded Arbel, Joseph Zohar, Doron Todder, and Hagit Cohen. 2022. "MDMA Treatment Paired with a Trauma-Cue Promotes Adaptive Stress Responses in a Translational Model of PTSD in Rats." *Translational Psychiatry* 12 (1): 1–11. https://doi.org/10.1038/s41398-022-01952-8.

Baur, Volker, Jürgen Hänggi, Nicolas Langer, and Lutz Jäncke. 2013. "Resting-State Functional and Structural Connectivity within an Insula-Amygdala Route Specifically Index State and Trait Anxiety." *Biological Psychiatry* 73 (1): 85–92. https://doi.org/10.1016/j.biopsych.2012.06.003.

Beck, A. T., R. A. Steer, R. Ball, and W. Ranieri. 1996. "Comparison of Beck Depression Inventories -IA and -II in Psychiatric Outpatients." *Journal of Personality Assessment* 67 (3): 588–97. https://doi.org/10.1207/s15327752jpa6703_13.

Bedi, Gillinder, K. Luan Phan, Mike Angstadt, and Harriet de Wit. 2009. "Effects of MDMA on Sociability and Neural Response to Social Threat and Social Reward." *Psychopharmacology* 207 (1): 73–83. https://doi.org/10.1007/s00213-009-1635-z.

Benjamini, Yoav, and Yosef Hochberg. 1995. "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing." *Journal of the Royal Statistical Society. Series B (Methodological)* 57 (1): 289–300.

Blake, Dudley, Frank Weathers, LN Nagy, D. Kaloupek, G. Klauminzer, Dennis Charney, and Terence Keane. 1990. "A Clinician Rating Scale for Assessing Current and Lifetime PTSD: The CAPS-1." *Behav. Ther.* 18 (January).

Bluhm, Robyn L., Peter C. Williamson, Elizabeth A. Osuch, Paul A. Frewen, Todd K. Stevens, Kristine Boksman, Richard W. J. Neufeld, Jean Théberge, and Ruth A. Lanius. 2009. "Alterations in Default Network Connectivity in Posttraumatic Stress Disorder Related to Early-Life Trauma." *Journal of Psychiatry and Neuroscience* 34 (3): 187–94.

Brady, Kathleen T, Therese Killeen, Tim Brewerton, and Sylvia Lucerini. 2000. "Comorbidity of Psychiatric Disorders and Posttraumatic Stress Disorder." *J Clin Psychiatry* 61: 11.

Bremner, J. Douglas, Eric Vermetten, Christian Schmahl, Viola Vaccarino, Meena Vythilingam, Nadeem Afzal, Christian Grillon, and Dennis S. Charney. 2005. "Positron Emission Tomographic Imaging of Neural Correlates of a Fear Acquisition and Extinction Paradigm in Women with Childhood Sexual-Abuse-Related Post-Traumatic Stress Disorder." *Psychological Medicine* 35 (6): 791–806. https://doi.org/10.1017/S0033291704003290.

Buysse, D. J., C. F. Reynolds, T. H. Monk, S. R. Berman, and D. J. Kupfer. 1989. "The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research." *Psychiatry Research* 28 (2): 193–213. https://doi.org/10.1016/0165-1781(89)90047-4.

Carhart-Harris, R. L., M. B. Wall, D. Erritzoe, M. Kaelen, B. Ferguson, I. De Meer, M. Tanner, et al. 2014. "The Effect of Acutely Administered MDMA on Subjective and BOLD-FMRI Responses to Favourite and Worst Autobiographical Memories." *International Journal of Neuropsychopharmacology* 17 (4): 527–40. https://doi.org/10.1017/S1461145713001405.

Carhart-Harris, Robin L., Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, et al. 2015. "The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers

Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity." *Biological Psychiatry* 78 (8): 554–62. https://doi.org/10.1016/j.biopsych.2013.12.015.

Carlson, Eve Bernstein, and Frank W. Putnam. 1993. "An Update on the Dissociative Experiences Scale." *Dissociation: Progress in the Dissociative Disorders* 6 (1): 16–27.

Cauda, Franco, Giuliano Geminiani, Federico D'Agata, Katiuscia Sacco, Sergio Duca, Andrew P. Bagshaw, and Andrea E. Cavanna. 2010. "Functional Connectivity of the Posteromedial Cortex." *PLoS ONE* 5 (9): e13107. https://doi.org/10.1371/journal.pone.0013107.

Cavanna, Andrea E., and Michael R. Trimble. 2006. "The Precuneus: A Review of Its Functional Anatomy and Behavioural Correlates." *Brain: A Journal of Neurology* 129 (Pt 3): 564–83. https://doi.org/10.1093/brain/awl004.

Chiao, Joan Y., Tetsuya Iidaka, Heather L. Gordon, Junpei Nogawa, Moshe Bar, Elissa Aminoff, Norihiro Sadato, and Nalini Ambady. 2008. "Cultural Specificity in Amygdala Response to Fear Faces." *Journal of Cognitive Neuroscience* 20 (12): 2167–74. https://doi.org/10.1162/jocn.2008.20151.

Cullen, Kathryn R., Melinda K. Westlund, Bonnie Klimes-Dougan, Bryon A. Mueller, Alaa Houri, Lynn E. Eberly, and Kelvin O. Lim. 2014. "Abnormal Amygdala Resting-State Functional Connectivity in Adolescent Depression." *JAMA Psychiatry* 71 (10): 1138–47. https://doi.org/10.1001/jamapsychiatry.2014.1087.

Dale, A. M., B. Fischl, and M. I. Sereno. 1999. "Cortical Surface-Based Analysis. I. Segmentation and Surface Reconstruction." *NeuroImage* 9 (2): 179–94. https://doi.org/10.1006/nimg.1998.0395.

Desikan, Rahul S., Florent Ségonne, Bruce Fischl, Brian T. Quinn, Bradford C. Dickerson, Deborah Blacker, Randy L. Buckner, et al. 2006. "An Automated Labeling System for Subdividing the Human Cerebral Cortex on MRI Scans into Gyral Based Regions of Interest." *NeuroImage* 31 (3): 968–80. https://doi.org/10.1016/j.neuroimage.2006.01.021.

Doss, Manoj K., Jessica Weafer, David A. Gallo, and Harriet de Wit. 2018. "MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections." *Neuropsychopharmacology* 43 (4): 791–800. https://doi.org/10.1038/npp.2017.171.

Dunn, Barnaby D., Ramaris E. German, Gabi Khazanov, Colin Xu, Steven D. Hollon, and Robert J. DeRubeis. 2020. "Changes in Positive and Negative Affect During Pharmacological Treatment and Cognitive Therapy for Major Depressive Disorder: A Secondary Analysis of Two Randomized Controlled Trials." *Clinical Psychological Science* 8 (1): 36–51. https://doi.org/10.1177/2167702619863427.

Ehlers, Anke. 2010. "Understanding and Treating Unwanted Trauma Memories in Posttraumatic Stress Disorder." *Zeitschrift Für Psychologie / Journal of Psychology* 218 (2): 141–45. https://doi.org/10.1027/0044-3409/a000021.

Etkin, Amit, and Tor D. Wager. 2007. "Functional Neuroimaging of Anxiety: A Meta-Analysis of Emotional Processing in PTSD, Social Anxiety Disorder, and Specific Phobia." *American Journal of Psychiatry* 164 (10): 1476–88. https://doi.org/10.1176/appi.ajp.2007.07030504.

Feduccia, Allison A., and Michael C. Mithoefer. 2018. "MDMA-Assisted Psychotherapy for PTSD: Are Memory Reconsolidation and Fear Extinction Underlying Mechanisms?" *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 84 (June): 221–28. https://doi.org/10.1016/j.pnpbp.2018.03.003.

Feurer, Cope, Jagan Jimmy, Fini Chang, Scott A. Langenecker, K. Luan Phan, Olusola Ajilore, and Heide Klumpp. 2021. "Resting State Functional Connectivity Correlates of Rumination and Worry in Internalizing Psychopathologies." *Depression and Anxiety* 38 (5): 488–97. https://doi.org/10.1002/da.23142.

Friston, K. J., S. Williams, R. Howard, R. S. Frackowiak, and R. Turner. 1996. "Movement-Related Effects in FMRI Time-Series." *Magnetic Resonance in Medicine* 35 (3): 346–55. https://doi.org/10.1002/mrm.1910350312.

Garrett, Amy, Judith A. Cohen, Sanno Zack, Victor Carrion, Booil Jo, Joseph Blader, Alexis Rodriguez, Thomas J. Vanasse, Allan L. Reiss, and W. Stewart Agras. 2019. "Longitudinal Changes in Brain Function Associated with Symptom Improvement in Youth with PTSD." *Journal of Psychiatric Research* 114 (July): 161–69. https://doi.org/10.1016/j.jpsychires.2019.04.021.

Goetter, Elizabeth M., Eric Bui, Rebecca A. Ojserkis, Rebecca J. Zakarian, Rebecca Weintraub Brendel, and Naomi M. Simon. 2015. "A Systematic Review of Dropout From Psychotherapy for Posttraumatic Stress Disorder Among Iraq and Afghanistan Combat Veterans." *Journal of Traumatic Stress* 28 (5): 401–9. https://doi.org/10.1002/jts.22038.

Guze, Samuel B. 1995. "Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV)." *American Journal of Psychiatry* 152 (8): 1228–1228. https://doi.org/10.1176/ajp.152.8.1228.

Hake, Holly S., Jazmyne K. P. Davis, River R. Wood, Margaret K. Tanner, Esteban C. Loetz, Anais Sanchez, Mykola Ostrovskyy, et al. 2019. "3,4-Methylenedioxymethamphetamine (MDMA) Impairs the Extinction and Reconsolidation of Fear Memory in Rats." *Physiology & Behavior* 199 (February): 343–50. https://doi.org/10.1016/j.physbeh.2018.12.007.

Harnett, Nathaniel G., Adam M. Goodman, and David C. Knight. 2020. "PTSD-Related Neuroimaging Abnormalities in Brain Function, Structure, and Biochemistry." *Experimental Neurology* 330 (August): 113331. https://doi.org/10.1016/j.expneurol.2020.113331.

Helpman, Liat, Xi Zhu, Sigal Zilcha-Mano, Benjamin Suarez-Jimenez, Amit Lazarov, Bret Rutherford, and Yuval Neria. 2021. "Reversed Patterns of Resting State Functional Connectivity for Females vs. Males in Posttraumatic Stress Disorder." *Neurobiology of Stress* 15 (November): 100389. https://doi.org/10.1016/j.ynstr.2021.100389.

Huijstee, Jytte van, and Eric Vermetten. 2018. "The Dissociative Subtype of Post-Traumatic Stress Disorder: Research Update on Clinical and Neurobiological Features." *Current Topics in Behavioral Neurosciences* 38: 229–48. https://doi.org/10.1007/7854_2017_33.

Jerome, Lisa, Allison A. Feduccia, Julie B. Wang, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer, and Rick Doblin. 2020. "Long-Term Follow-up Outcomes of MDMA-Assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials." *Psychopharmacology* 237 (8): 2485–97. https://doi.org/10.1007/s00213-020-05548-2.

Ke, Jun, Li Zhang, Rongfeng Qi, Weihui Li, Cailan Hou, Yuan Zhong, Zhong He, Lingjiang Li, and Guangming Lu. 2016. "A Longitudinal FMRI Investigation in Acute Post-Traumatic Stress Disorder (PTSD)." *Acta Radiologica* 57 (11): 1387–95. https://doi.org/10.1177/0284185115585848.

Kleim, Birgit, Franziska Wallott, and Anke Ehlers. 2008. "Are Trauma Memories Disjointed from Other Autobiographical Memories in   Posttraumatic Stress Disorder? An

Experimental Investigation." *Behavioural and Cognitive Psychotherapy* 36 (2): 221–34. https://doi.org/10.1017/S1352465807004080.

Lanius, R. A., R. L. Bluhm, N. J. Coupland, K. M. Hegadoren, B. Rowe, J. Théberge, R. W. J. Neufeld, P. C. Williamson, and M. Brimson. 2010. "Default Mode Network Connectivity as a Predictor of Post-Traumatic Stress Disorder Symptom Severity in Acutely Traumatized Subjects." *Acta Psychiatrica Scandinavica* 121 (1): 33–40. https://doi.org/10.1111/j.1600-0447.2009.01391.x.

Lanius, R. A., R. Bluhm, U. Lanius, and C. Pain. 2006. "A Review of Neuroimaging Studies in PTSD: Heterogeneity of Response to Symptom Provocation." *Journal of Psychiatric Research* 40 (8): 709–29. https://doi.org/10.1016/j.jpsychires.2005.07.007.

Lanius, R. A., P. C. Williamson, M. Densmore, K. Boksman, M. A. Gupta, R. W. Neufeld, J. S. Gati, and R. S. Menon. 2001. "Neural Correlates of Traumatic Memories in Posttraumatic Stress Disorder: A Functional MRI Investigation." *The American Journal of Psychiatry* 158 (11): 1920–22. https://doi.org/10.1176/appi.ajp.158.11.1920.

Lanius, Ruth A., Peter C. Williamson, Kristine Boksman, Maria Densmore, Madhulika Gupta, Richard W. J. Neufeld, Joseph S. Gati, and Ravi S. Menon. 2002. "Brain Activation during Script-Driven Imagery Induced Dissociative Responses in PTSD: A Functional Magnetic Resonance Imaging Investigation." *Biological Psychiatry* 52 (4): 305–11. https://doi.org/10.1016/s0006-3223(02)01367-7.

LeDoux, Joseph. 2003. "The Emotional Brain, Fear, and the Amygdala." *Cellular and Molecular Neurobiology* 23 (4): 727–38. https://doi.org/10.1023/A:1025048802629.

Lewis, Catrin, Neil P. Roberts, Samuel Gibson, and Jonathan I. Bisson. 2020. "Dropout from Psychological Therapies for Post-Traumatic Stress Disorder (PTSD) in Adults: Systematic Review and Meta-Analysis." *European Journal of Psychotraumatology* 11 (1): 1709709. https://doi.org/10.1080/20008198.2019.1709709.

Liberzon, Israel, Stephan F. Taylor, Richard Amdur, Tara D. Jung, Kenneth R. Chamberlain, Satoshi Minoshima, Robert A. Koeppe, and Lorraine M. Fig. 1999. "Brain Activation in PTSD in Response to Trauma-Related Stimuli." *Biological Psychiatry* 45 (7): 817–26. https://doi.org/10.1016/S0006-3223(98)00246-7.

Liddell, Belinda J., and Laura Jobson. 2016. "The Impact of Cultural Differences in Self-Representation on the Neural Substrates of Posttraumatic Stress Disorder." *European Journal of Psychotraumatology* 7 (1): 30464. https://doi.org/10.3402/ejpt.v7.30464.

Maddock, R. J. 1999. "The Retrosplenial Cortex and Emotion: New Insights from Functional Neuroimaging of the Human Brain." *Trends in Neurosciences* 22 (7): 310–16. https://doi.org/10.1016/s0166-2236(98)01374-5.

Maples-Keller, Jessica L., Seth D. Norrholm, Mark Burton, Collin Reiff, Callan Coghlan, Tanja Jovanovic, Carly Yasinski, et al. 2022. "A Randomized Controlled Trial of 3,4-Methylenedioxymethamphetamine (MDMA) and Fear Extinction Retention in Healthy Adults." *Journal of Psychopharmacology (Oxford, England)*, February, 2698811211069124. https://doi.org/10.1177/02698811211069124.

Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G., et al. 2021. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." *Nature Medicine* 27 (6): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.

Mithoefer, Michael C., Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, and Rick Doblin. 2019.

"MDMA-Assisted Psychotherapy for Treatment of PTSD: Study Design and Rationale for Phase 3 Trials Based on Pooled Analysis of Six Phase 2 Randomized Controlled Trials." *Psychopharmacology* 236 (9): 2735–45. https://doi.org/10.1007/s00213-019-05249-5.

Mithoefer, Michael C., Ann T. Mithoefer, Allison A. Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, et al. 2018. "3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial." *The Lancet Psychiatry* 5 (6): 486–97. https://doi.org/10.1016/S2215-0366(18)30135-4.

Mithoefer, Michael C., Mark T. Wagner, Ann T. Mithoefer, Lisa Jerome, and Rick Doblin. 2011. "The Safety and Efficacy of {+/-}3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study." *Journal of Psychopharmacology (Oxford, England)* 25 (4): 439–52. https://doi.org/10.1177/0269881110378371.

Nicholson, Andrew A., Maria Densmore, Paul A. Frewen, Jean Théberge, Richard WJ Neufeld, Margaret C. McKinnon, and Ruth A. Lanius. 2015. "The Dissociative Subtype of Posttraumatic Stress Disorder: Unique Resting-State Functional Connectivity of Basolateral and Centromedial Amygdala Complexes." *Neuropsychopharmacology* 40 (10): 2317–26. https://doi.org/10.1038/npp.2015.79.

Patel, Ronak, R. Nathan Spreng, Lisa M. Shin, and Todd A. Girard. 2012. "Neurocircuitry Models of Posttraumatic Stress Disorder and beyond: A Meta-Analysis of Functional Neuroimaging Studies." *Neuroscience & Biobehavioral Reviews* 36 (9): 2130–42. https://doi.org/10.1016/j.neubiorev.2012.06.003.

Peng, Xiaoling, Way K. W. Lau, Chanyu Wang, Lingfang Ning, and Ruibin Zhang. 2020. "Impaired Left Amygdala Resting State Functional Connectivity in Subthreshold Depression Individuals." *Scientific Reports* 10 (1): 17207. https://doi.org/10.1038/s41598-020-74166-x.

Pitman, Roger K., Ann M. Rasmusson, Karestan C. Koenen, Lisa M. Shin, Scott P. Orr, Mark W. Gilbertson, Mohammed R. Milad, and Israel Liberzon. 2012. "Biological Studies of Post-Traumatic Stress Disorder." *Nature Reviews Neuroscience* 13 (11): 769–87. https://doi.org/10.1038/nrn3339.

Rauch, Scott L., Lisa M. Shin, and Elizabeth A. Phelps. 2006. "Neurocircuitry Models of Posttraumatic Stress Disorder and Extinction: Human Neuroimaging Research--Past, Present, and Future." *Biological Psychiatry* 60 (4): 376–82. https://doi.org/10.1016/j.biopsych.2006.06.004.

Ravindran, Lakshmi N., and Murray B. Stein. 2009. "Pharmacotherapy of PTSD: Premises, Principles, and Priorities." *Brain Research* 1293 (October): 24–39. https://doi.org/10.1016/j.brainres.2009.03.037.

Ridderbusch, Isabelle C., Adrian Wroblewski, Yunbo Yang, Jan Richter, Maike Hollandt, Alfons O. Hamm, Hans-Ulrich Wittchen, et al. 2021. "Neural Adaptation of Cingulate and Insular Activity during Delayed Fear Extinction: A Replicable Pattern across Assessment Sites and Repeated Measurements." *NeuroImage* 237 (August): 118157. https://doi.org/10.1016/j.neuroimage.2021.118157.

Roy, Amy Krain, Zarrar Shehzad, Daniel S. Margulies, A. M. Clare Kelly, Lucina Q. Uddin, Kristin Gotimer, Bharat B. Biswal, F. Xavier Castellanos, and Michael P. Milham. 2009. "Functional Connectivity of the Human Amygdala Using Resting State FMRI." *NeuroImage* 45 (2): 614–26. https://doi.org/10.1016/j.neuroimage.2008.11.030.

Sartory, Gudrun, Jan Cwik, Helge Knuppertz, Benjamin Schürholt, Morena Lebens, Rüdiger J. Seitz, and Ralf Schulze. 2013. "In Search of the Trauma Memory: A Meta-Analysis of Functional Neuroimaging Studies of Symptom Provocation in Posttraumatic Stress Disorder (PTSD)." *PloS One* 8 (3): e58150. https://doi.org/10.1371/journal.pone.0058150.

Sestieri, Carlo, Maurizio Corbetta, Gian Luca Romani, and Gordon L. Shulman. 2011. "Episodic Memory Retrieval, Parietal Cortex, and the Default Mode Network: Functional and Topographic Analyses." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 31 (12): 4407–20. https://doi.org/10.1523/JNEUROSCI.3335-10.2011.

Singh, Manpreet K., Ryan G. Kelley, Kiki D. Chang, and Ian H. Gotlib. 2015. "Intrinsic Amygdala Functional Connectivity in Youth With Bipolar I Disorder." *Journal of the American Academy of Child & Adolescent Psychiatry* 54 (9): 763–70. https://doi.org/10.1016/j.jaac.2015.06.016.

Smith, Stephen M., Mark Jenkinson, Mark W. Woolrich, Christian F. Beckmann, Timothy E. J. Behrens, Heidi Johansen-Berg, Peter R. Bannister, et al. 2004. "Advances in Functional and Structural MR Image Analysis and Implementation as FSL." *NeuroImage* 23 Suppl 1: S208-219. https://doi.org/10.1016/j.neuroimage.2004.07.051.

Smith, Stephen M., and Thomas E. Nichols. 2009. "Threshold-Free Cluster Enhancement: Addressing Problems of Smoothing, Threshold Dependence and Localisation in Cluster Inference." *NeuroImage* 44 (1): 83–98. https://doi.org/10.1016/j.neuroimage.2008.03.061.

Spreng, R. Nathan, Raymond A. Mar, and Alice S. N. Kim. 2009. "The Common Neural Basis of Autobiographical Memory, Prospection, Navigation, Theory of Mind, and the Default Mode: A Quantitative Meta-Analysis." *Journal of Cognitive Neuroscience* 21 (3): 489–510. https://doi.org/10.1162/jocn.2008.21029.

Sripada, Rebecca, Anthony King, Sarah Garfinkel, Xin Wang, Chandra Sripada, Robert Welsh, and Israel Liberzon. 2012. "Altered Resting-State Amygdala Functional Connectivity in Men with Posttraumatic Stress Disorder." *Journal of Psychiatry & Neuroscience* 37 (4): 241–49. https://doi.org/10.1503/jpn.110069.

Stoddard, Joel, Derek Hsu, Richard C. Reynolds, Melissa A. Brotman, Monique Ernst, Daniel S. Pine, Ellen Leibenluft, and Daniel P. Dickstein. 2015. "Aberrant Amygdala Intrinsic Functional Connectivity Distinguishes Youths with Bipolar Disorder from Those with Severe Mood Dysregulation." *Psychiatry Research: Neuroimaging* 231 (2): 120–25. https://doi.org/10.1016/j.pscychresns.2014.11.006.

Strawn, Jeffrey R., Samantha M. Bitter, Wade A. Weber, Wen-Jang Chu, Rachel M. Whitsel, Caleb Adler, Michel A. Cerullo, James Eliassen, Stephen M. Strakowski, and Melissa P. DelBello. 2012. "Neurocircuitry of Generalized Anxiety Disorder in Adolescents: A Pilot Functional Neuroimaging and Functional Connectivity Study." *Depression and Anxiety* 29 (11): 939–47. https://doi.org/10.1002/da.21961.

Suzuki, Akinobu, Sheena A. Josselyn, Paul W. Frankland, Shoichi Masushige, Alcino J. Silva, and Satoshi Kida. 2004. "Memory Reconsolidation and Extinction Have Distinct

Temporal and Biochemical Signatures." *Journal of Neuroscience* 24 (20): 4787–95. https://doi.org/10.1523/JNEUROSCI.5491-03.2004.

Svoboda, Eva, Margaret C. McKinnon, and Brian Levine. 2006. "The Functional Neuroanatomy of Autobiographical Memory: A Meta-Analysis." *Neuropsychologia* 44 (12): 2189–2208. https://doi.org/10.1016/j.neuropsychologia.2006.05.023.

Tedeschi, R. G., and L. G. Calhoun. 1996. "The Posttraumatic Growth Inventory: Measuring the Positive Legacy of Trauma." *Journal of Traumatic Stress* 9 (3): 455–71. https://doi.org/10.1007/BF02103658.

Toazza, Rudineia, Alexandre Rosa Franco, Augusto Buchweitz, Roberta Dalle Molle, Danitsa Marcos Rodrigues, Roberta Sena Reis, Amanda Brondani Mucellini, et al. 2016. "Amygdala-Based Intrinsic Functional Connectivity and Anxiety Disorders in Adolescents and Young Adults." *Psychiatry Research: Neuroimaging* 257 (November): 11–16. https://doi.org/10.1016/j.pscychresns.2016.09.010.

VanElzakker, Michael B., Lindsay K. Staples-Bradley, and Lisa M. Shin. 2018. "The Neurocircuitry of Fear and PTSD." In *Sleep and Combat-Related Post Traumatic Stress Disorder*, edited by Eric Vermetten, Anne Germain, and Thomas C. Neylan, 111–25. New York, NY: Springer. https://doi.org/10.1007/978-1-4939-7148-0_10.

Veer, Ilya M., Nicole Y. L. Oei, Philip Spinhoven, Mark A. van Buchem, Bernet M. Elzinga, and Serge A. R. B. Rombouts. 2011. "Beyond Acute Social Stress: Increased Functional Connectivity between Amygdala and Cortical Midline Structures." *NeuroImage* 57 (4): 1534–41. https://doi.org/10.1016/j.neuroimage.2011.05.074.

Walpola, Ishan C., Timothy Nest, Leor Roseman, David Erritzoe, Amanda Feilding, David J. Nutt, and Robin L. Carhart-Harris. 2017. "Altered Insula Connectivity under MDMA." *Neuropsychopharmacology* 42 (11): 2152–62. https://doi.org/10.1038/npp.2017.35.

Wang, Julie B., Jessica Lin, Leah Bedrosian, Allison Coker, Ilsa Jerome, Allison Feduccia, Alia Lilienstein, et al. 2021. "Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder." *Journal of Humanistic Psychology*, June, 00221678211023663. https://doi.org/10.1177/00221678211023663.

Wei, Shengnan, Miao Chang, Ran Zhang, Xiaowei Jiang, Fei Wang, and Yanqing Tang. 2018. "Amygdala Functional Connectivity in Female Patients with Major Depressive Disorder with and without Suicidal Ideation." *Annals of General Psychiatry* 17 (1): 37. https://doi.org/10.1186/s12991-018-0208-0.

Werff, S. J. A. van der, J. N. Pannekoek, I. M. Veer, M.-J. van Tol, A. Aleman, D. J. Veltman, F. G. Zitman, S. a. R. B. Rombouts, B. M. Elzinga, and N. J. A. van der Wee. 2013. "Resting-State Functional Connectivity in Adults with Childhood Emotional Maltreatment." *Psychological Medicine* 43 (9): 1825–36. https://doi.org/10.1017/S0033291712002942.

Winkler, Anderson M., Gerard R. Ridgway, Matthew A. Webster, Stephen M. Smith, and Thomas E. Nichols. 2014. "Permutation Inference for the General Linear Model." *NeuroImage* 92 (May): 381–97. https://doi.org/10.1016/j.neuroimage.2014.01.060.

Woolrich, Mark W., Timothy E. J. Behrens, Christian F. Beckmann, Mark Jenkinson, and Stephen M. Smith. 2004. "Multilevel Linear Modelling for FMRI Group Analysis Using Bayesian Inference." *NeuroImage* 21 (4): 1732–47. https://doi.org/10.1016/j.neuroimage.2003.12.023.

Yang, Yang, Fanlu Jia, Wai Ting Siok, and Li Hai Tan. 2017. "The Role of Anxiety in Stuttering: Evidence from Functional Connectivity." *Neuroscience* 346 (March): 216–25. https://doi.org/10.1016/j.neuroscience.2016.11.033.

Young, Kymberly D., Greg J. Siegle, Masaya Misaki, Vadim Zotev, Raquel Phillips, Wayne C. Drevets, and Jerzy Bodurka. 2018. "Altered Task-Based and Resting-State Amygdala Functional Connectivity Following Real-Time FMRI Amygdala Neurofeedback Training in Major Depressive Disorder." *NeuroImage: Clinical* 17 (January): 691–703. https://doi.org/10.1016/j.nicl.2017.12.004.

Young, M. B., R. Andero, K. J. Ressler, and L. L. Howell. 2015. "3,4-Methylenedioxymethamphetamine Facilitates Fear Extinction Learning." *Translational Psychiatry* 5 (9): e634–e634. https://doi.org/10.1038/tp.2015.138.

Young, Matthew B., Seth D. Norrholm, Lara M. Khoury, Tanja Jovanovic, Sheila A.M. Rauch, Collin M. Reiff, Boadie W. Dunlop, Barbara O. Rothbaum, and Leonard L. Howell. 2017. "Inhibition of Serotonin Transporters Disrupts the Enhancement of Fear Memory Extinction by 3,4-Methylenedioxymethamphetamine (MDMA)." *Psychopharmacology* 234 (19): 2883–95. https://doi.org/10.1007/s00213-017-4684-8.

Zhang, Sheng, and Chiang-shan R. Li. 2012. "Functional Connectivity Mapping of the Human Precuneus by Resting State FMRI." *NeuroImage* 59 (4): 3548–62. https://doi.org/10.1016/j.neuroimage.2011.11.023.